IL284510B2 - Crystalline forms of succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-h7-pyrrolo[3,2-d]pyrimidine-6-carboxylic acid dimethylamide - Google Patents

Crystalline forms of succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-h7-pyrrolo[3,2-d]pyrimidine-6-carboxylic acid dimethylamide

Info

Publication number
IL284510B2
IL284510B2 IL284510A IL28451021A IL284510B2 IL 284510 B2 IL284510 B2 IL 284510B2 IL 284510 A IL284510 A IL 284510A IL 28451021 A IL28451021 A IL 28451021A IL 284510 B2 IL284510 B2 IL 284510B2
Authority
IL
Israel
Prior art keywords
ribociclib
modification
cancer
salt
crystalline form
Prior art date
Application number
IL284510A
Other languages
English (en)
Hebrew (he)
Other versions
IL284510A (en
IL284510B1 (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL284510A publication Critical patent/IL284510A/en
Publication of IL284510B1 publication Critical patent/IL284510B1/en
Publication of IL284510B2 publication Critical patent/IL284510B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL284510A 2019-01-23 2020-01-23 Crystalline forms of succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-h7-pyrrolo[3,2-d]pyrimidine-6-carboxylic acid dimethylamide IL284510B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962795799P 2019-01-23 2019-01-23
PCT/IB2020/050544 WO2020152629A1 (en) 2019-01-23 2020-01-23 New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide

Publications (3)

Publication Number Publication Date
IL284510A IL284510A (en) 2021-08-31
IL284510B1 IL284510B1 (en) 2025-06-01
IL284510B2 true IL284510B2 (en) 2025-10-01

Family

ID=69467591

Family Applications (1)

Application Number Title Priority Date Filing Date
IL284510A IL284510B2 (en) 2019-01-23 2020-01-23 Crystalline forms of succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-h7-pyrrolo[3,2-d]pyrimidine-6-carboxylic acid dimethylamide

Country Status (8)

Country Link
US (2) US12390468B2 (cg-RX-API-DMAC10.html)
EP (1) EP3914353A1 (cg-RX-API-DMAC10.html)
JP (2) JP2022517842A (cg-RX-API-DMAC10.html)
CN (1) CN113316471A (cg-RX-API-DMAC10.html)
AU (2) AU2020211071A1 (cg-RX-API-DMAC10.html)
CA (1) CA3124015A1 (cg-RX-API-DMAC10.html)
IL (1) IL284510B2 (cg-RX-API-DMAC10.html)
WO (1) WO2020152629A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020002123A (es) 2017-08-25 2020-09-18 Sicor Soc It Corticosteroidi S R L Sales de ribociclib y formas en estado sólido de las mismas.
WO2020152629A1 (en) 2019-01-23 2020-07-30 Novartis Ag New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
EP4762058A1 (en) * 2023-08-18 2026-06-24 Alembic Pharmaceuticals Limited Polymorph of ribociclib salt
WO2025144118A1 (en) * 2023-12-27 2025-07-03 Deva Holding Novel polymorph of ribociclib dihydrochloride dihydrate and method of preparation
US20250319032A1 (en) 2024-04-15 2025-10-16 Novartis Ag Pharmaceutical compositions of ribociclib

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012064805A1 (en) * 2010-11-10 2012-05-18 Novartis Ag Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
US20180282342A1 (en) * 2014-12-12 2018-10-04 Crystal Pharmatech Co., Ltd. Salt of Pyrrolo[2,3-D]pyrimidine Compound and Novel Polymorph of Salt
WO2019111160A1 (en) * 2017-12-04 2019-06-13 Sun Pharmaceutical Industries Limited Crystalline forms of ribociclib succinate

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI992711A1 (it) 1999-12-27 2001-06-27 Novartis Ag Composti organici
EA012926B1 (ru) 2001-12-20 2010-02-26 Оси Фармасьютикалз, Инк. Пирролопиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
JP2008506761A (ja) 2004-07-22 2008-03-06 アステックス、セラピューティックス、リミテッド プロテインキナーゼ阻害剤としてのチアゾールおよびイソチアゾール誘導体
BRPI0612997A2 (pt) 2005-07-22 2010-12-14 Qualcomm Incorporated dispositivos mems e respectivos mÉtodos de fabrico
WO2007075783A2 (en) 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
ES2910444T3 (es) 2012-02-24 2022-05-12 Nokia Technologies Oy Método y aparato para establecer una conexión con una red de acceso basándose en información de interfuncionamiento de red de acceso
CN105111215B (zh) * 2014-12-12 2019-06-18 苏州晶云药物科技股份有限公司 一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法
WO2016091221A1 (zh) 2014-12-12 2016-06-16 苏州晶云药物科技有限公司 吡咯并[2,3-d]嘧啶化合物的盐及盐的新晶型
US10323035B2 (en) 2015-04-01 2019-06-18 Crystal Pharmatech Co., Ltd. Co-crystal of a CDK inhibitor and an MEK inhibitor and process of preparation thereof
MX2020002123A (es) 2017-08-25 2020-09-18 Sicor Soc It Corticosteroidi S R L Sales de ribociclib y formas en estado sólido de las mismas.
WO2019123364A1 (en) 2017-12-22 2019-06-27 Shilpa Medicare Limited Novel polymorphs of ribociclib mono succinate
WO2019142206A1 (en) 2018-01-20 2019-07-25 Natco Pharma Limited An improved process for the preparation of ribociclib succinate and its novel crystalline forms thereof
TWI675662B (zh) * 2018-05-17 2019-11-01 中化合成生技股份有限公司 瑞博西尼琥珀酸鹽(Ribociclib succinate salt)晶型B、C及D與其衍生物,以及其等之製造方法與藥物組合物
WO2020152629A1 (en) 2019-01-23 2020-07-30 Novartis Ag New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012064805A1 (en) * 2010-11-10 2012-05-18 Novartis Ag Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
US20180282342A1 (en) * 2014-12-12 2018-10-04 Crystal Pharmatech Co., Ltd. Salt of Pyrrolo[2,3-D]pyrimidine Compound and Novel Polymorph of Salt
WO2019111160A1 (en) * 2017-12-04 2019-06-13 Sun Pharmaceutical Industries Limited Crystalline forms of ribociclib succinate

Also Published As

Publication number Publication date
CA3124015A1 (en) 2020-07-30
EP3914353A1 (en) 2021-12-01
AU2023200724A1 (en) 2023-03-09
US20230042479A1 (en) 2023-02-09
JP2024099797A (ja) 2024-07-25
US12390468B2 (en) 2025-08-19
US20250281492A1 (en) 2025-09-11
AU2023200724B2 (en) 2025-01-23
CN113316471A (zh) 2021-08-27
WO2020152629A1 (en) 2020-07-30
KR20210119444A (ko) 2021-10-05
IL284510A (en) 2021-08-31
IL284510B1 (en) 2025-06-01
AU2020211071A1 (en) 2021-07-15
JP2022517842A (ja) 2022-03-10

Similar Documents

Publication Publication Date Title
AU2023200724B2 (en) New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide
AU2016203534B2 (en) Salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
JP2024037930A (ja) Tlr7/tlr8阻害剤の結晶形態
JPH11509865A (ja) 5―(2―(4―(1,2―ベンズイソチアゾール―3―イル)―1―ピペラジニル)エチル)―6―クロロ―1,3―ジヒドロ―2(1h)―インドール―2―オン(=ジプラシドン)のメシレート三水和物、その調製法およびドーパミンd2アンタゴニストとしてのその使用法
JP2016128501A (ja) プリン誘導体の結晶性形態
CN102421780A (zh) 氨基磺酸((1s,2s,4r)-4-{4-[(1s)-2,3-二氢-1h-茚-1-基氨基]-7h-吡咯并[2,3-d]嘧啶-7-基}-2-羟基环戊基)甲酯盐酸盐
KR20210102497A (ko) 피리디노일피페리딘 5-ht1f 작용제에 관한 조성물 및 방법
US20240350501A1 (en) SALT OF N-(2,6-DIETHYLPHENYL)-8-({4-[4-(DIMETHYLAMINO) PIPERIDIN-1-YL]-2-METHOXYPHENYL}AMINO)-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-h]QUINAZOLINE-3-CARBOXAMIDE, ITS PREPARATION, AND FORMULATIONS CONTAINING IT
US9884856B2 (en) Crystal form of Dabrafenib mesylate and preparation method thereof
JP6816036B2 (ja) ヒストン脱アセチル化阻害剤の結晶形態
TWI705065B (zh) 嗎啉衍生物的鹽及其晶型、其製備方法及藥物組成物、用途
TW201625621A (zh) Pi3k抑制劑之形式
WO2024251230A1 (zh) 一种plk1激酶抑制剂的盐型、晶型及其制备方法和应用
WO2020065667A1 (en) Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor
RU2857779C2 (ru) Новые кристаллические формы сукцинатной соли диметиламида 7-циклопентил-2-(5-пиперазин-1-илпиридин-2-иламино)-7h-пирроло[2,3-d]пиримидин-6-карбоновой кислоты
CN111484488A (zh) 一种b-raf激酶二聚体抑制剂的稳定结晶形式a
CN113840605B (zh) N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺盐酸盐的结晶形式及其用途
WO2025223554A1 (zh) 一种嘧啶并氮杂环类化合物的晶型及其制备方法及应用